Sanofi's New Leadership Faces Looming Patent Cliff
Sanofi's wide lineup of branded drugs and vaccines and robust pipeline creates strong cash flows and a narrow economic moat.
Sanofi SA ADR SNY
Bulls Say, Bears Say
Bulls
Immunology drug Dupixent holds strong pricing power and market share across several indications.
Bears
Sanofi suffered several disappointing readouts starting in 2025, adding pressure to develop or acquire assets that could replace Dupixent before its loss of exclusivity.
News
-
Sanofi and Keke Palmer team up to urge parents to help protect babies from serious RSV with BEYFORTUS®
-
FDA Approves Seasonal Covid-19 Vaccines From Moderna, Pfizer, BioNTech, Novavax — Update
-
Sanofi Shares Slide After CEO Signals Challenges to Fill Drug Pipeline
-
Sanofi Raises Guidance as New CEO Looks to Revamp Drug Pipeline
-
Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO
-
Scribe Therapeutics to Sell 7.15 Million Shares at $13-$15 Each in IPO
-
EU Seeks Views on Sanofi's Concessions to End Competition Probe — Update
-
EU Seeks Views on Sanofi's Concessions to End Competition Probe
Articles & Videos
-
As Biopharma Turns to China, ESG Risks and Geopolitics Remain in Focus
-
9 New 5-Star Stocks This Week
-
18 of the Best Stocks and ETFs to Buy Based on 2026 Expert Forecasts
-
Best Sustainable Companies to Own: 2025 Edition
-
Best Healthcare Companies to Own: 2025 Edition
-
The Best Companies to Own: 2025 Edition
Trading Information
- Previous Close Price
- $44.24
- Day Range
- $43.25–43.70
- 52-Week Range
- $40.89–52.68
- Bid/Ask
- $43.38 / $43.39
- Shares Outstanding
- 2.40B
- Market Cap
- $103.84B
- Volume/Avg
- 2M / 3M
Key Statistics
- Price/Earnings (Normalized)
- 12.57
- Price/Sales
- 1.88
- Dividend Yield (Trailing)
- 5.47%
- Dividend Yield (Forward)
- 5.47%
- Dividend Payment Schedule
- Jun
- Total Yield
- 10.62%
Company Profile
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 74,846
- Website
- https://www.sanofi.com
Competitors
Valuation
|
Metric
|
SNY
|
MRK
|
NVS
|
|---|---|---|---|
Price/Earnings (Normalized) | 12.57 | 46.83 | 18.43 |
Price/Book Value | 1.48 | 8.85 | 7.32 |
Price/Sales | 1.88 | 5.60 | 5.44 |
Price/Cash Flow | 7.77 | 16.83 | 16.06 |
Price/Earnings
SNY
MRK
NVS
Financial Strength
|
Metric
|
SNY
|
MRK
|
NVS
|
|---|---|---|---|
Quick Ratio | 0.49 | 0.71 | 0.55 |
Current Ratio | 0.99 | 1.32 | 0.86 |
Interest Coverage | 8.05 | 4.28 | 11.90 |
Quick Ratio
SNY
MRK
NVS
Profitability
|
Metric
|
SNY
|
MRK
|
NVS
|
|---|---|---|---|
Return on Assets (Normalized) | 7.96% | 6.27% | 14.74% |
Return on Equity (Normalized) | 14.96% | 16.68% | 39.06% |
Return on Invested Capital (Normalized) | 11.28% | 9.82% | 21.25% |
Return on Assets
SNY
MRK
NVS
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|HlP@^%c | LOCK|t% | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|xy#<gcD | LOCK|P@ | $663B | |||
| AbbVie Inc
ABBV
| LOCK|KHS!@D | LOCK|bMf | $453B | |||
| Merck & Co Inc
MRK
| LOCK|?XJSP# | LOCK|>!V | $371B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|>?LGr!^F | LOCK|<w | $353B | |||
| Novartis AG ADR
NVS
| LOCK|x!B%<KK@ | LOCK|FL | $305B | |||
| AstraZeneca PLC
AZN
| LOCK|pC<NttN | LOCK|Cx& | $252B | |||
| Amgen Inc
AMGN
| LOCK|>%P#W>hj | LOCK|hp | $236B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|Rp@s@#w | LOCK|!Wc | $206B | |||
| Gilead Sciences Inc
GILD
| LOCK|thx$FR | LOCK|hb | $187B |
United States